Inozyme Pharma, Inc. (NASDAQ:INZY) Short Interest Update

Inozyme Pharma, Inc. (NASDAQ:INZY - Get Free Report) saw a significant increase in short interest in the month of December. As of December 31st, there was short interest totalling 3,700,000 shares, an increase of 11.4% from the December 15th total of 3,320,000 shares. Approximately 8.4% of the shares of the company are sold short. Based on an average daily volume of 545,100 shares, the days-to-cover ratio is presently 6.8 days.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of INZY. Deerfield Management Company L.P. Series C bought a new position in shares of Inozyme Pharma in the second quarter worth about $52,000. Virtu Financial LLC bought a new position in Inozyme Pharma in the 3rd quarter worth approximately $64,000. SG Americas Securities LLC acquired a new position in Inozyme Pharma during the 3rd quarter worth $81,000. Cubist Systematic Strategies LLC bought a new position in Inozyme Pharma in the 2nd quarter valued at $84,000. Finally, The Manufacturers Life Insurance Company boosted its position in Inozyme Pharma by 14.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 21,427 shares of the company's stock valued at $96,000 after buying an additional 2,690 shares during the last quarter. Institutional investors own 88.30% of the company's stock.

Analyst Upgrades and Downgrades

INZY has been the subject of a number of research analyst reports. Piper Sandler cut their target price on shares of Inozyme Pharma from $43.00 to $30.00 and set an "overweight" rating for the company in a research report on Monday, January 13th. HC Wainwright increased their target price on Inozyme Pharma from $14.00 to $16.00 and gave the company a "buy" rating in a research note on Friday, January 10th. Raymond James started coverage on Inozyme Pharma in a research report on Thursday, December 12th. They issued an "outperform" rating and a $26.00 price target on the stock. Wedbush reissued an "outperform" rating and issued a $12.00 price objective on shares of Inozyme Pharma in a research report on Friday, January 10th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $23.00 target price on shares of Inozyme Pharma in a research report on Wednesday, November 6th. Nine analysts have rated the stock with a buy rating, According to MarketBeat.com, Inozyme Pharma currently has a consensus rating of "Buy" and a consensus target price of $18.33.

Inozyme Pharma Stock Performance

INZY stock remained flat at $1.36 during trading on Friday. The company had a trading volume of 1,359,588 shares, compared to its average volume of 431,124. The company has a current ratio of 7.68, a quick ratio of 7.68 and a debt-to-equity ratio of 0.51. The firm's fifty day moving average is $2.75 and its two-hundred day moving average is $4.28. Inozyme Pharma has a twelve month low of $1.32 and a twelve month high of $7.80. The stock has a market capitalization of $87.37 million, a P/E ratio of -0.87 and a beta of 1.35.

Inozyme Pharma (NASDAQ:INZY - Get Free Report) last posted its earnings results on Tuesday, November 5th. The company reported ($0.39) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.05. On average, analysts expect that Inozyme Pharma will post -1.59 earnings per share for the current year.

About Inozyme Pharma

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.